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W
ith the advent of more intensive glucose
management, hypoglycemia has emerged as a
primary limitation in the treatment of insulin-
dependent diabetes. It is now recognized that
the increased incidence of hypoglycemia derives not only
from imperfect insulin replacement but also from impaired
counterregulation and hypoglycemic unawareness (1).
The latter two observations have led to a renewed interest
in the mechanisms underlying hypoglycemic detection. As
a result of intensive research over the past decade, the
traditional hypothalamocentric model of glucose sensing
has been replaced with one emphasizing a widespread
neural network involving numerous aspects of the central
nervous system, as well as peripheral sensory input. Thus,
in addition to the ventromedial hypothalamus, the para-
ventricular hypothalamus, arcuate nucleus, area postrema,
nucleus of the solitary tract, and dorsal motor nucleus all
appear to play important roles (2,3). In the periphery,
important glucose sensors have been identiﬁed in the
carotid bodies (4), gastrointestinal tract (5), and portal-
mesenteric vein (6). For hypoglycemic detection, the
glucose sensors of the portal-mesenteric vein have gar-
nered the most attention. Animal studies have repeatedly
demonstrated that blocking portal glucose sensing via
portal glucose infusion (7) or denervating the portal vein
(8) substantially suppresses the sympathoadrenal re-
sponse to hypoglycemia. More recently, it was shown that
portal-mesenteric vein glucose sensing is particularly im-
portant when hypoglycemia develops slowly and, under
these conditions, modulates over 90% of the sympathoad-
renal response to hypoglycemia (9).
While portal vein glucose sensing appears to be con-
served across several species (7,9,10), demonstration of
consistent ﬁndings in humans has proven elusive. An
obvious limitation for human studies is the lack of direct
access to the portal vein, which severely constrains exper-
imental interventions. To circumvent this problem, Ros-
setti et al. (11) employed an oral glucose load to elevate
portal glucose concentration during a hyperinsulinemic-
hypoglycemic clamp. Oral glucose was administered be-
fore the clamp to establish a portal-arterial gradient before
the onset of hypoglycemia. Hypoglycemia was then al-
lowed to develop slowly—an important aspect of this
study considering the previously mentioned animal exper-
iments and the clinical relevance. Despite these efforts,
they observed no effect of the oral glucose load on
counterregulatory or symptomatic responses to hypogly-
cemia. The authors conclude that the portal glucose
sensor plays no signiﬁcant role in hypoglycemic detection
for humans. This is not the ﬁrst time such an approach has
been employed in an attempt to elucidate the potential
role of portal glucose sensing in humans (12–14). While all
previous reports demonstrated a signiﬁcant impact of an
oral glucose load on the hormonal responses to hypogly-
cemia, results have been anything but consistent.
In addition to the negative ﬁndings for Rossetti et al.,
oral glucose during a hyperinsulinimic-hypoglycemic
clamp has been shown to suppress (14), augment (13), and
initially suppress and then augment (12) the sympathoad-
renal response to hypoglycemia in humans. As noted by
Rossetti et al. (11), subtle differences in the respective
protocols (e.g., rate of fall in glycemia, the timing and/or
mass of the oral glucose load) may explain some of the
observed differences. However, critical to the interpreta-
tion of these ﬁndings is the assumption that the oral
glucose load actually elevates the portal vein glucose
concentration above the glycemic threshold for the dura-
tion of the experiment. Because portal glucose concentra-
tion cannot be measured directly in humans, it must be
based on estimated rates of glucose appearance and portal
blood ﬂow. A number of sophisticated modeling ap-
proaches employing multiple tracers have been developed
for estimating the appearance of an oral glucose load
(15,16) but, to date, have not been used in studies of portal
glucose sensing in humans. Further confounding estimates
of portal glucose concentration is the wide range of values
reported for human portal blood ﬂow, (10–18 ml  kg
1 
min
1 [17]), which may increase substantially in response
to oral glucose ingestion.
Alternatively, the disparate ﬁndings for these human
studies may result from the complexity of introducing an
oral glucose load, as opposed to simply infusing glucose in
the portal vein (Fig. 1). As noted in one recent review (3),
glucose sensing of an oral glucose load begins in the oral
cavity and continues in the gut, the portal-mesenteric vein,
and, ﬁnally, the systemic circulation. In particular, the
gastrointestinal tract is now recognized as an important
locus for glucose detection. The ability to sense glucose in
the luminal contents of the gut not only allows for intrinsic
control but also provides important sensory feedback to
the central nervous system via extrinsic afferent nerves
and blood-borne peptides (5). Many of the peptides se-
creted by the enteroendocrine cells of the gut (e.g.,
glucagon-like peptide 1 [GLP-1], glucose-dependent insuli-
notropic peptide, and peptide YY) are now well recognized
for their impact on glucose and energy homeostasis. While
considerable insight has been gained regarding their role
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under hypoglycemic conditions is poorly understood and
not always obvious. For example, the ability of GLP-1 to
suppress glucagon secretion is apparently lost under hy-
poglycemic conditions (18). Also, the vagal glucose-sensi-
tive afferents of the portal vein, which are inhibited by
glucose, are activated by GLP-1 (19), a peptide released in
response to oral glucose (5). While vagal afferents are
apparently not involved in hypoglycemic detection at the
portal vein (20), if the spinal glucose-sensitive afferents (8)
demonstrate similar reciprocal responses to glucose and
GLP-1, this might explain some of the observed disparity
in these human studies. It is also important to recognize
that all peripheral glucose sensory input, i.e., gut, portal-
mesenteric, and gustatory, converges on the nucleus of the
solitary tract, where local glycemic conditions are likely to
impact on the eventual efferent response (3).
Given the marked disparity in ﬁndings for humans, it is
perhaps premature to conclude that hypoglycemic detec-
tion at the portal vein is not important for humans as
proposed by Rossetti et al. (11). Beyond the substantial
technical obstacles faced by such studies, there is the
fundamental question of whether glucose introduced to
the portal circulation via the gut is equivalent to a direct
glucose infusion. As our understanding of the neural
network underlying glucose sensing improves, it is likely
that at least some of the apparent differences in human
and animal hypoglycemic detection will be resolved.
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FIG. 1. Glucose sensory input: For an oral glucose load, afferent inputs include the oral cavity, gastrointestinal tract, and portal-superior
mesenteric veins (vagal and spinal), all of which converge on the nucleus of the solitary tract (NTS). In addition, gut peptides released by an oral
glucose load can activate sensory neurons in the gastrointestinal tract and portal vein, as well as activate the central nervous system directly.
For portal vein glucose infusion during a hyperinsulinimic-hypoglycemic clamp, input is restricted to glucose sensing afferents in the
portal-mesenteric vein.
HYPOGLYCEMIC DETECTION AT THE PORTAL VEIN
22 DIABETES, VOL. 58, JANUARY 2009augments the counterregulatory hormone response during insulin-induced
hypoglycemia in humans. J Clin Endocrinol Metabol 86:645–648, 2001
14. Smith D, Pernet A, Reid H, Bingham E, Rosenthal J, Macdonald I, Umpleby
A, Amiel SA: The role of hepatic portal glucose sensing in modulating
responses to hypoglycemia in man. Diabetologia 45:1416–1424, 2002
15. Basu R, Di Camillo B, Toffolo G, Basu A, Shah P, Vella A, Rizza R, Cobelli
C: Use of a novel triple-tracer approach to assess postprandial glucose
metabolism. Am J Physiol 284:E55–E69, 2003
16. Livesey G, Wilson PDG, Dainty JR, Brown JC, Faulks RM, Roe MA,
Newman TA, Eagles J, Mellon FA, Greenwood RH: Simultaneous time-
varying systemic appearance of oral and hepatic glucose in adults moni-
tored with stable isotopes. Am J Physiol 275:E717–E728, 1998
17. Tamada T, Moriyasu F, Ono S, Shimizu K, Kajimura K, Soh Y, Kawasaki T,
Kimura T, Yamashita Y, Someda H: Portal blood ﬂow: measurement with
MR imaging. Radiology 173:639–644, 1989
18. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hufner
M, Schmiegel WH: Effects of glucagon-like peptide 1 on counterregulatory
hormone responses, cognitive functions, and insulin secretion during
hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy
volunteers. J Clin Endocrinol Metab 87:1239–1246, 2002
19. Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A: Vagal
hepatopancreatic reﬂex effect evoked by intraportal appearance of tGLP-1.
Am J Physiol 271:E803–E813, 1996
20. Jackson P, Pagliassotti M, Shiota M, Neal D, Cardin S, Cherrington A:
Effects of vagal blockade on the counterregulatory response to insulin-
induced hypoglycemia in the dog. Am J Physiol 273:E1178–E1188, 1997
C.M. DONOVAN AND M. BOHLAND
DIABETES, VOL. 58, JANUARY 2009 23